The Solaris DE Endoprosthesis for the Treatment of AV Access Stenosis or Occlusion

Recruiting now · Not applicable

Conditions studied: Venous Stenosis, Venous Occlusion, Chronic Renal Failure

In brief

The goal of this clinical trial is to demonstrate the safety and efficacy of Solaris DE Endoprosthesis in the treatment of stenosis or occlusion within the outflow circuit of the dialysis access including arteriovenous (AV) fistula and synthetic AV graft. Participants will be treated with Solaris DE Endoprosthesis. Researchers will compare the treatment with investigational product to Percutaneous Transluminal Angioplasty (PTA) alone within the AV fistula cohort in order to demonstrate superiority of Solaris DE.

Key facts

Study ID

NCT06096142

Run by

Scitech Produtos Medicos SA

People needed

120

Starts

2024-08-30

Expected to finish

2028-02-01

Last updated by the study team

2026-03-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The participant has a mature AV Fistula (AVF) or Graft (AVG) in the arm created ≥ 30 days before the initial procedure and is in use for dialysis therapy
• The participant has clinical and/or hemodynamic evidence of a venous outflow obstruction or AV fistula or graft dysfunction. The stenotic lesion is ≥ 50%, with a maximum length of 8 cm and a distal reference vessel diameter from 4.0 mm to 9.0 mm
• The participan provides written informed consent prior to any study-specific procedure
• The participan is willing to undergo all follow-up evaluations according to the specified schedule over 24 months
• Angiographic Inclusion Criteria:
• The target lesion originates ≥ 3 cm from the cannulation segment (needling zone)
• The target lesion is located:
• In one arm (including the cephalic arch) in a participant with AVF, and not in the cannulation segment, OR
• In the anastomosis or juxta-anastomosis in a participant with AVF (a juxta-anastomosis is defined as a location where the stent crosses the venous anastomosis)
• The target lesion includes a de novo stenotic lesion or restenosis
• The target lesion is ≥ 5 cm from the arterial anastomosis
• The target lesion has ≥ 50% stenosis according to the operator's visual judgment
• The distal reference vessel diameter of the target lesion is between 4.0 mm and 9.0 mm by the operator's visual judgment
• Single or multiple target lesions measuring ≤ 8 cm in total length by the operator's visual judgment
• Single or multiple target lesions should be covered by a single stent or multiple overlapping stents, provided they are treated as a single lesion with a maximum length of 8 cm
• Successful target lesion pre-dilatation is defined as crossover of the guidewir resulting in full expansion of the pre-dilatation balloon
• The participant has up to 1 (one) non-target lesion in the access circuit requiring intervention in the initial procedure. The non-target lesion must be at least 10 cm away from the target lesion. The non-target lesion can only be treated with standard PTA alone
• Does not have stent implanted or it has been in the access circuit for ≥ 30 days since placement and patent with ≤ 30% stenosis and located ≥ 5 cm from the target lesion
• The non-target lesion must be successfully treated at the time of the initial procedure (success measured as ≤30% residual stenosis and no complications).

You may not qualify if…

• Pregnant, breastfeeding or with intention to become pregnant in the next year
• The participant has any major endovascular or surgical procedure planned (including in the access circuit) within 30 days of the initial procedure
• It was not possible to pre-dilate the lesion to be treated with Solaris DE
• Planned surgical revision of the access site
• Known or suspected infection of the hemodialysis access site, systemic infection and/or sepsis
• Patients on immunosuppressive therapy
• Known active coagulopathy or bleeding diathesis
• Known hypersensitivity to nickel titanium alloy, contrast or sirolimus
• Contraindication to antiplatelet, anticoagulant or thrombolytic therapies
• Known allergy to contrast agents or medications administered to perform endovascular intervention that cannot be adequately premedicated
• Life expectancy of less than 12 months
• Has a stent or endoprosthesis located anywhere in the AV access circuit that is not patent (> 30% stenosis) or implanted < 30 days
• The participant's hemodialysis access is expected to be abandoned within 6 months
• The participantis is enrolled in another trial involving an investigational product (pharmaceutical, biological or medical device)
• The patient has a permanent central venous catheter (CVC) for dialysis access, except when its use is temporary, as a bridge to treatment through the access circuit, with a plan for removal after a successful dialysis session after the initial procedure
• Angiographic Exclusion Criteria:
• The target lesion is located inside an endoprosthesis
• Target lesion treatment would involve the cannulation segment (needling zone)
• The target lesion is < 5 cm from the arterial anastomosis
• There was a dissection or rupture of the treated vessel during the initial treatment that could not be controlled
• Evidence of an aneurysm, pseudoaneurysm or acute thrombus (i.e. one that has been treated ≤ 15 days) within the target lesion
• The target lesion is, and/or Solaris DE would be placed anywhere:
• Through the elbow
• In a region that causes bending of the endoprosthesis or bony protrusion over it
• In the cannulation segment (needling zone)

Where it is running

• Hospital Ana Nery — Salvador, Estado de Bahia, Brazil (enrolling)
• Afya Hospital Dia LTDA — Brasília, Federal District, Brazil (enrolling)
• Hospital das Clínicas da UFMG/EBSERH — Belo Horizonte, Minas Gerais, Brazil (enrolling)
• Real Hospital Português de Beneficência em Pernambuco — Recife, Pernambuco, Brazil (enrolling)
• Hospital Universitário Pedro Ernesto - UERJ — Rio de Janeiro, Rio de Janeiro, Brazil (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.